These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 22264792)

  • 1. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
    Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
    Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma.
    Ju HQ; Ying H; Tian T; Ling J; Fu J; Lu Y; Wu M; Yang L; Achreja A; Chen G; Zhuang Z; Wang H; Nagrath D; Yao J; Hung MC; DePinho RA; Huang P; Xu RH; Chiao PJ
    Nat Commun; 2017 Feb; 8():14437. PubMed ID: 28232723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
    Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
    Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-β signaling.
    Krantz SB; Shields MA; Dangi-Garimella S; Cheon EC; Barron MR; Hwang RF; Rao MS; Grippo PJ; Bentrem DJ; Munshi HG
    Mol Cancer Res; 2011 Oct; 9(10):1294-304. PubMed ID: 21856775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PRKD1 promoter is a target of the KRas-NF-κB pathway in pancreatic cancer.
    Döppler H; Panayiotou R; Reid EM; Maimo W; Bastea L; Storz P
    Sci Rep; 2016 Sep; 6():33758. PubMed ID: 27649783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression.
    Rielland M; Cantor DJ; Graveline R; Hajdu C; Mara L; Diaz Bde D; Miller G; David G
    J Clin Invest; 2014 May; 124(5):2125-35. PubMed ID: 24691445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB.
    Melisi D; Niu J; Chang Z; Xia Q; Peng B; Ishiyama S; Evans DB; Chiao PJ
    Mol Cancer Res; 2009 May; 7(5):624-33. PubMed ID: 19435817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network.
    Ying H; Elpek KG; Vinjamoori A; Zimmerman SM; Chu GC; Yan H; Fletcher-Sananikone E; Zhang H; Liu Y; Wang W; Ren X; Zheng H; Kimmelman AC; Paik JH; Lim C; Perry SR; Jiang S; Malinn B; Protopopov A; Colla S; Xiao Y; Hezel AF; Bardeesy N; Turley SJ; Wang YA; Chin L; Thayer SP; DePinho RA
    Cancer Discov; 2011 Jul; 1(2):158-69. PubMed ID: 21984975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer.
    Kapoor A; Yao W; Ying H; Hua S; Liewen A; Wang Q; Zhong Y; Wu CJ; Sadanandam A; Hu B; Chang Q; Chu GC; Al-Khalil R; Jiang S; Xia H; Fletcher-Sananikone E; Lim C; Horwitz GI; Viale A; Pettazzoni P; Sanchez N; Wang H; Protopopov A; Zhang J; Heffernan T; Johnson RL; Chin L; Wang YA; Draetta G; DePinho RA
    Cell; 2014 Jul; 158(1):185-197. PubMed ID: 24954535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.
    Maniati E; Bossard M; Cook N; Candido JB; Emami-Shahri N; Nedospasov SA; Balkwill FR; Tuveson DA; Hagemann T
    J Clin Invest; 2011 Dec; 121(12):4685-99. PubMed ID: 22056382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.
    Luo Y; Yang Y; Liu M; Wang D; Wang F; Bi Y; Ji J; Li S; Liu Y; Chen R; Huang H; Wang X; Swidnicka-Siergiejko AK; Janowitz T; Beyaz S; Wang G; Xu S; Bialkowska AB; Luo CK; Pin CL; Liang G; Lu X; Wu M; Shroyer KR; Wolff RA; Plunkett W; Ji B; Li Z; Li E; Li X; Yang VW; Logsdon CD; Abbruzzese JL; Lu W
    Gastroenterology; 2019 Nov; 157(5):1413-1428.e11. PubMed ID: 31352001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-802 Suppresses Acinar-to-Ductal Reprogramming During Early Pancreatitis and Pancreatic Carcinogenesis.
    Ge W; Goga A; He Y; Silva PN; Hirt CK; Herrmanns K; Guccini I; Godbersen S; Schwank G; Stoffel M
    Gastroenterology; 2022 Jan; 162(1):269-284. PubMed ID: 34547282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation.
    Zhuang Z; Ju HQ; Aguilar M; Gocho T; Li H; Iida T; Lee H; Fan X; Zhou H; Ling J; Li Z; Fu J; Wu M; Li M; Melisi D; Iwakura Y; Xu K; Fleming JB; Chiao PJ
    Clin Cancer Res; 2016 Mar; 22(6):1432-44. PubMed ID: 26500238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo.
    Qiu W; Sahin F; Iacobuzio-Donahue CA; Garcia-Carracedo D; Wang WM; Kuo CY; Chen D; Arking DE; Lowy AM; Hruban RH; Remotti HE; Su GH
    Oncotarget; 2011 Nov; 2(11):862-73. PubMed ID: 22113502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis.
    Yuan P; He XH; Rong YF; Cao J; Li Y; Hu YP; Liu Y; Li D; Lou W; Liu MF
    Cancer Res; 2017 Jan; 77(1):100-111. PubMed ID: 27793842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of susceptibility loci in a mouse model of KRASG12D-driven pancreatic cancer.
    Jorgenson TC; Williams BR; Wendland A; Bilger A; Sandgren EP; Drinkwater NR
    Cancer Res; 2010 Nov; 70(21):8398-406. PubMed ID: 20959479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early elevations of RAS protein level and activity are critical for the development of PDAC in the context of inflammation.
    Ma J; Gong F; Kim E; Du JX; Leung C; Song Q; Logsdon CD; Luo Y; Li X; Lu W
    Cancer Lett; 2024 Apr; 586():216694. PubMed ID: 38307409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.